Frontiers in Drug Research and Development for Inflammatory Bowel Disease

Overview of attention for article published in Frontiers in Pharmacology, June 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 14 X posts from 14 X users, with an upper bound of 15,317 followers.

RT @velezmeca: Ozanimod, amiselimod, Etrasimod, Abrilumab, Risankizumab, Brazikumab, filgotinib.. Nuevos fármacos para EII https://t.co/…

RT @velezmeca: Ozanimod, amiselimod, Etrasimod, Abrilumab, Risankizumab, Brazikumab, filgotinib.. Nuevos fármacos para EII https://t.co/…

RT @velezmeca: Ozanimod, amiselimod, Etrasimod, Abrilumab, Risankizumab, Brazikumab, filgotinib.. Nuevos fármacos para EII https://t.co/…

RT @velezmeca: Ozanimod, amiselimod, Etrasimod, Abrilumab, Risankizumab, Brazikumab, filgotinib.. Nuevos fármacos para EII https://t.co/…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.